Related Articles |
EGFR is not amplified in ameloblastoma.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Mar 06;:
Authors: Costa V, Fregnani ER, Fonseca FP, Abreu Alves F, Pinto CAL, Kaminagakura E
Abstract
OBJECTIVE: The aim of this study was to investigate alterations in the EGFR gene and its protein expression for a better understanding of the biologic behavior of ameloblastoma.
STUDY DESIGN: Twenty-five samples of ameloblastoma were selected, and dual-color fluorescence in situ hybridization assay was performed. The results of the assay and immunohistochemistry reaction for EGFR and Ki67 were associated with clinicopathologic features and recurrence.
RESULTS: All analyzed cases presented disomy without any gene polysomy or amplification. With regard to EGFR immunoexpression, 3 cases (12%) were considered negative, and 22 (88%) were positive, of which 13 (52%) were weak and 9 (36%) were strong. All samples presented low positivity for Ki67. There was no association between EGFR expression and clinicopathologic features or recurrence (P > .05). In some cases, EGFR immunoexpression was observed without gene amplification.
CONCLUSIONS: Ameloblastoma development, progression, or recurrence does not appear to be related to EGFR amplification or polysomy.
PMID: 29602688 [PubMed - as supplied by publisher]
from #ENT-PubMed via ola Kala on Inoreader https://ift.tt/2E7I8LL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου